Skip to content

Efficacy of IFABONDTM Synthetic Glue for Fixation of Implanted Material in Laparoscopic Sacrocolpopexy: a Prospective Multicenter Study

Efficacy of IFABONDTM Synthetic Glue for Fixation of Implanted Material in Laparoscopic Sacrocolpopexy: a Prospective Multicenter Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02011373
Acronym
PRO-COLLE
Enrollment
70
Registered
2013-12-13
Start date
2013-11-06
Completion date
2018-10-30
Last updated
2025-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Medial and/or Anterior Genital Prolapse

Keywords

prolapse, laparoscopic sacrocolpopexy, IFABONDTM glue

Brief summary

Laparoscopic sacrocolpopexy is the consensual attitude of choice in genital prolapse but incurs problems of tolerance of implanted material. As an alternative to stapling and suturing, which cause vaginal erosion, we present a fixation technique using a sterile synthetic liquid tissue glue: IFABOND™. A non-randomised prospective multicenter study will assess efficacy in terms of 12-month failure of prolapse correction.

Interventions

PROCEDUREfixation technique using a sterile synthetic liquid tissue glue: IFABOND™

Sponsors

Vitalitec
CollaboratorUNKNOWN
Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Woman aged 18 years or more * Stage III or IV medial and/or anterior genital prolapse on the Pelvic Organ Prolapse Quantification (POP-Q) classification (hysterocele and/or cystocele), requiring surgical correction * Patient requesting surgery for the trouble caused by the prolapse

Exclusion criteria

* Prolapse of POP-Q stage \<III or without functional impact * Unacceptable postoperative risk disclosed on interview: coagulation disorder, immune disorder, evolutive disease, etc. * Impaired lower-limb range of motion preventing positioning for surgery * Pregnancy or intended pregnancy during study period * Evolutive or latent infection or signs of tissue necrosis on clinical examination * Non-controlled diabetes (glycated haemoglobin \>8%) * Treatment impacting immune response (immunomodulators), ongoing or within previous month * History of pelvic region radiation therapy, at any time * History of pelvic cancer * Non-controlled evolutive spinal pathology * Known hypersensitivity to one of the implant components (polypropylene) * Cyanoacrylate hypersensitivity * Formaldehyde hypersensitivity * Inability to understand information provided * No national health insurance cover; prisoner, or ward of court

Design outcomes

Primary

MeasureTime frame
Percentage prolapse correction failure12 months post-surgery

Secondary

MeasureTime frame
Percentage prolapse correction failure24 months post-surgery
Percentage immediate postoperative failure1 month post-surgery
Complications ratePeroperative and 1, 12 and 24 months post-surgery
Quality of life score1, 12 and 24 months post-surgery

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026